Table 3.

Percentage (%) and absolute number of peripheral blood lymphocyte subsets in convalescent COVID-19 patients who suffered from mild, moderate, or severe disease and in healthy controls. Median and interquartile range are indicated. n.s. Not significant

	No-COVID	Mild	Moderate	Severe
					p Value
CD3%	83.5	79	76	80	n.s.
	(79–88.7)	(73–85)	(74.5–77)	(74.2–81.5)
CD3	1320	1270	1079	1409
	(1011–2222)	(763–2060)	(751–1296)	(1103–1854)
CD4%	53.5	48	50	44	n.s.
	(48–57)	(34–53)	(45–55)	(38–54)
CD4	895	713	681	852
	(802–1577)	(398–1088)	(440–828)	(690–1171)
CD8%	25	30	24	30	n.s.
	(22–32)	(24–35)	(23–30)	(23–38)
CD8#	448	435	357	512
	(278–840)	(282–666)	(247–432)	(330–737)
CD16%	8	7	11	7	n.s.
	(5–14)	(4–12)	(5–13)	(5–15)
CD16	177	98	117	143
	(66–251)	(88–153)	(97–168)	(78–198)
CD19%	5	6	10	5	n.s.
	(4–10)	(5–9)	(7–12)	(4–8)
CD19	179	103	133	113
	(58–241)	(70–128)	(64–151)	(75–156)
CD3 + DR+ %	13	22	17	23	n.s
	(12–16)	(13–23)	(10–20)	(11–31)
CD3 + DR+	290	252	186	492
	(190–391)	(180–390)	(94–350)	(109–630)
CD4 + DR+ %	4	5	4	5	n.s.
	(3–6)	(4–7)	(3–5)	(4–9)
CD4 + DR+	64	92	68	117
	(38–95)	(74–107)	(30–116)	(70–160)
CD8 + DR+ %	8	14	5	11	n.s.
	(5–10)	(5–17)	(3–12)	(8–18)
CD8 + DR+	166	178	72	226
	(118–240)	(111–222)	(31–171)	(88–316)
CD16 + DR+ %	1	1	1	2	n.s.
	(0–3)	(0–2)	(0–2)	(0–4)
CD16 + DR+	14 (13–54)	16 (5–23)	10 (5–30)	34 (2–63)